Cancer Research
Newswire |
CALGARY, Alberta, June 20 /PRNewswire/ -- Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that following U.S. Food and Drug Administration (FDA) review, the Company is initiating a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers. The Principal Investigator is Dr. Monica Mita of the Cancer Therapy and Research Center, University of Texas Health Science Center in San Antonio, Texas (CTRC at UTHSCSA).
"REOLYSIN(R) is one of the more exciting…
Newswire |
AMSTERDAM, Netherlands, June 19 /PRNewswire/ --
Agendia BV has announced the official opening of the company's new headquarters yesterday at Amsterdam's Science Park at Watergraafsmeer, Kruislaan 406. The Grand Opening ceremony was officiated by Dr. Rene Bernards, Chief Scientific Officer at Agendia and the Honourable Director General Mrs. R.M. Bergkamp, on behalf of the Honourable Mrs. Maria van der Hoeven, Minster of Economic Affairs for The Netherlands.
"Agendia has a distinguished history of providing exceptional high quality diagnostic testing services that provide valuable information…
Newswire |
LOS ANGELES, California, June 19 /PRNewswire/ -- Canopus BioPharma, Inc. (OTC: CBIA), has confirmed the efficacy of its oncology candidate, CB1400, as a tumor reducing agent and has also demonstrated the synergistic effect of this drug in combination with both cisplatin and cetuximab (Erbitux) in two mice lung cancer models.
Chairman of Canopus BioPharma, Dr. Patrick Prendergast, stated, "We at Canopus are encouraged with the discovery of this new use for CB1400 to increase efficacy and reduce toxicity issues associated with conventional chemotherapeutic agents."
CB1400, a former…
Newswire |
KVISTGÅRD, Denmark, June 19 /PRNewswire/ -- Bavarian Nordic's cancer research unit, BN ImmunoTherapeutics, has completed an interim analysis of its first two clinical studies with MVA-BN(R)-HER2, a cancer vaccine immunotherapy for breast cancer patients.
The first study, performed in the US, is evaluating MVA-BN(R)-HER2 treatment following chemotherapy and Herceptin(R) treatment. In the second study, performed in Serbia and Poland, MVA-BN(R)-HER2 is being evaluated following only chemotherapy or in combination with single-agent taxane chemotherapy. Both studies evaluate treatment of…
Radiation is dangerous. In high doses it is certainly lethal and chronic exposure is linked to the development of cancer. That's why we have bomb shelters and canned food.
But what if a short-term controlled exposure to a low dose of radiation were good for our health? Don Luckey, emeritus professor at the University of Missouri, claims just that in the International Journal of Low Radiation.
Luckey was also the nutrition consultant for NASA's Apollo 11 to 17 moon missions and has spent the last several years developing the concept of improving health through exposure to low-dose radiation…
Patients diagnosed with colon cancer who had abundant vitamin D in their blood were less likely to die during a follow-up period than those who were deficient in the vitamin, according to a new study by scientists at Dana-Farber Cancer Institute.
The findings of the study -- the first to examine the effect of vitamin D among colorectal cancer patients -- merit further research, but it is too early to recommend supplements as a part of treatment, say the investigators from Dana-Farber and the Harvard School of Public Health.
In a report in the June 20 issue of the Journal of Clinical Oncology…
Newswire |
SAN DIEGO, California, June 18 /PRNewswire/ -- Germany is on the cutting edge in biotechnology R&D and is a top player in large- and clinical-scale production. Companies located in Germany are poised to profit from the latest developments in biomanufacturing. These were the results of an expert panel, at the BIO International Convention (BIO 2008) in San Diego, California on June 18th. Invest in Germany co-chaired the panel along with the CEO of a major transatlantic biotech consultancy.
Dr. Barbara Esch opened the discussion, entitled "Biomanufacturing Solutions: Case Studies from…
Newswire |
GENEVA, June 18 /PRNewswire/ --
- Bionomics and Merck Serono to Collaborate to Discover and Develop Novel, Oral Treatment for MS
- Collaboration Based on Novel Compounds That Allow Selective Inhibition of The Immune Cells Which Cause Nerve Cell Damage in Patients With MS
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that a Development and Licensing Agreement with Bionomics (ASX: BNO) was signed, under which Merck Serono would develop new treatments for multiple sclerosis (MS) and other autoimmune conditions based on compounds from Bionomics Kv1.3 program.
Under…
Newswire |
LOS ANGELES, California, June 18 /PRNewswire/ -- Canopus BioPharma, Inc. (OTC: CBIA), a biotechnology company developing pharmaceutical products and assay methods for patients suffering from infectious disease, radiation sickness, cancer and addiction, today announced the signing of a licensing agreement with the Wisconsin Alumni Research Foundation (WARF), an organization serving the University of Wisconsin-Madison scientific community by patenting the discoveries of UW-Madison researchers and licensing these technologies to leading companies in Wisconsin, the United States and worldwide.…
Newswire |
SAN DIEGO, June 18 /PRNewswire/ --
- Potent Adjuvant is a Toll-Like Receptor 3 (TLR3) Agonist
Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced that the company has developed a proprietary vaccine adjuvant, Poly IC-Poly Arginine (Poly-ICR), that has broad potential for use in both therapeutic and prophylactic vaccines.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO)
Poly-ICR is a Toll-like Receptor 3 (TLR3) agonist that when combined with a disease-specific antigen can induce both cytotoxic (T-cell) and antibody (B-cell) immune responses against that antigen.…